Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Analyst Optimism | Learn about Wall Street's bullish stance on Ascendis, with price targets ranging from $170 to $250 and a highly favorable consensus rating of 1.25. |
Financial Trajectory | Delve into Ascendis' projected revenue growth from €363.6 million in 2024 to €1.72 billion by 2027, with analysts expecting profitability by 2026. |
Market Dominance | Explore Ascendis' first-mover advantage in hypoparathyroidism treatment, with Yorvipath projected to become a multi-billion euro drug in a market of 90,000 U.S. patients. |
Pipeline Promise | Ascendis Pharma's innovative therapies for rare endocrine disorders show potential, with Yorvipath exceeding expectations and a promising achondroplasia treatment in development. |
Metrics to compare | ASND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASNDPeersSector | |
---|---|---|---|---|
P/E Ratio | −26.7x | −2.1x | −0.5x | |
PEG Ratio | −0.78 | 0.04 | 0.00 | |
Price / Book | −48.0x | 1.6x | 2.6x | |
Price / LTM Sales | 24.7x | 6.9x | 3.1x | |
Upside (Analyst Target) | 26.8% | 136.7% | 45.7% | |
Fair Value Upside | Unlock | 12.2% | 5.7% | Unlock |